Answers are grounded in this paper and cite their sources.
Preclinical evaluation demonstrates binding of a new SV2A PET imaging probe in neuropsychiatric diseases.
Synaptic vesicle glycoprotein 2A (SV2A) is a 12-pass transmembrane glycoprotein ubiquitously expressed in presynaptic vesicles. In vivo imaging of SV2A using PET has potential applications in the diagnosis and prognosis of a variety of neuropsychiatric diseases, e.g., Alzheimer’s disease, Parkinson’s disease, schizophrenia, multiple sclerosis, autism, epilepsy, stroke, traumatic brain injury, post-traumatic stress disorder, depression, etc. Herein, we report the synthesis and evaluation of a new 18F-labeled SV2A PET imaging probe, [18F]SynVesT-2, which possesses fast in vivo binding kinetics and high specific binding signals in non-human primate brain.
No takes yet. Share an insight, caveat, or question.
Cai et al. (2020) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: